NicOx : Garufi ... e la Rivoluzione Pharma (3 lettori)
- Creatore Discussione Yesod
- Data di Inizio
- Stato
tradermen
Forumer storico
buongiorno a tutti
Lunedì 23 Marzo 2009, 11:38
[FONT=arial,elvetica]Tassi: Euribor 3 mesi giu' a 1,56% [/FONT]
[FONT=arial,helvetica](ANSA) - ROMA, 23 MAR - Sempre piu' giu' l'Euribor a tre mesi, il tasso che le banche applicano fra loro per i prestiti di depositi trimestrali.Oggi e' sceso per la ventisettesima volta consecutiva, passando dall'1,57% di venerdi' all'1,56%. Risale allo 0,97%, invece, l'Euribor a una settimana, mentre quello a un mese e' diminuito dall'1,18% all'1,17%. I dati sono rilevati dall'European Banking Federation.
[/FONT]
Lunedì 23 Marzo 2009, 11:38
[FONT=arial,elvetica]Tassi: Euribor 3 mesi giu' a 1,56% [/FONT]
[FONT=arial,helvetica](ANSA) - ROMA, 23 MAR - Sempre piu' giu' l'Euribor a tre mesi, il tasso che le banche applicano fra loro per i prestiti di depositi trimestrali.Oggi e' sceso per la ventisettesima volta consecutiva, passando dall'1,57% di venerdi' all'1,56%. Risale allo 0,97%, invece, l'Euribor a una settimana, mentre quello a un mese e' diminuito dall'1,18% all'1,17%. I dati sono rilevati dall'European Banking Federation.
[/FONT]
tradermen
Forumer storico
logoramento testic-olaresenza fine!
tanto tra qualche settimana dovranno finirla con sto cinema patetico !
Kaimanooooo Prrrrrrrrr !
prendiamoci un po + di tempo......
diciamo entro l' estate sapremo tane cose....
poi se prima meglio..tradermen
Forumer storico
Biotech Could Follow Pharma's M&A Lead
Friday, March 20, 2009 6:13 PM
Mar. 20, 2009 (Investor's Business Daily) -- Much of the drug industry's attention has recently focused on mergers and acquisitions by the biggest of Big Pharma, including much-hyped unions between Pfizer and Wyeth, Merck and Schering-Plough, and Roche and Genentech.
Less attention has been paid to consolidation in the biotech sector, though some experts expect plenty of activity there, too.
In fact, it's already happening.
Roche's (RHHBY) March 12 buy of 100% of Genentech was one example.
Another is last week's announcement by Gilead Sciences (GILD) it will buy fellow biotech CV Therapeutics (CVTX). CV's board unanimously recommended shareholders accept Gilead's $20-a-share cash offer.
The deal is worth $1.4 billion. That's small potatoes compared to Pfizer's $60 billion for Wyeth (WYE) or Merck's (MRK) $4.1 billion, but it's still a harbinger, observers say.
There are plenty of M&A prospects within biotech's own community, says Michael Becker, president and CEO of consulting firm MD Becker Partners.
Biotech has different needs from Big Pharma, says Becker, a former CEO at both Cytogen and VioQuest Pharmaceuticals.
Pharma is cash-rich but pipeline poor. In contrast, biotechs might have promising pipelines, but don't have much cash.
A handful of biotechs are profitable, but they tend to be the industry's biggest names. The list includes Gilead, Amgen (AMGN), Celgene (CELG), Genzyme (GENZ) and Biogen Idec (BIIB).
Becker expects one of two things to happen soon.
"We'll see either a lot of companies disappear after their funds run out, or we'll see a wave of consolidation in biotech," he said.
He reckons 120 biotechs will run out of cash in three months or less.
With only speculative science as collateral, most small biotechs can't borrow in this market. And most can't go public, either, because it's a bad market for IPOs.
In a nutshell, small-cap biotech funding is broken, says Jason Kantor, analyst with RBC Capital Markets. "We're seeing a lot of small-cap companies swallowing the bitter pill, cutting people and programs."
While biotechs have not been afraid of being acquired by rich drugmakers, biotechs being bought by fellow biotechs is more attractive because it allows two entrepreneurial and innovative organizations to grow together, Becker says.
Many of the bigger biotechs might start pouncing as their smaller brethren grow more desperate to cash in.
"If you're Amgen or Biogen Idec, you're probably sitting on the sidelines waiting for companies to start running out of capital," Becker said.
Gilead outbid Japan's Astellas to get CV Therapeutics, which has never turned a profit. Gilead specializes in HIV/AIDS and liver disease treatments. It made the buy to grow its cardiac business.
Mergers within the biotech community are probable, says Kantor.
That's partly because biotechs buying biotechs need not fear a bidding war with Big Pharma. The recent activity showed that big drugmakers have a low appetite for risk, even though they know they need to do something about their pipelines, Kantor says.
Even Roche's buy of the remaining shares of Genentech it didn't previously own was more about saving money than expanding research.
"They're more comfortable with mergers that have cost savings as a major component of growth than they are with the high risk of clinical trials that come with buying more innovative growth companies," Kantor said.
Meanwhile, small cap biotechs, faced with a capital drought, will be more willing sellers. The buyers would be not only large biotechs but even some midcap biotechs that have cash.
Biotech buyers of biotech will be selective. They're more likely to put money into smaller biotechs that have products completing phase three clinical trials, Kantor says. "People don't like to buy early clinical trial risk."
He cites data showing that from 2005 to 2008, 80% of biotechs acquired had products on the market or had completed phase three.
In some cases, science won't be the motivation for an acquisition. Gilead bought CV Therapeutics for its sales force, Kantor says.
If cash-poor biotechs don't merge, they'll at least have to delay product development, says Damien Conover, Morningside biotech analyst and co-author of a report grading 63 biotechs by acquisition probability.
The top target is Ireland's Elan (ELN), developer of autoimmune and neurodegenerative therapies.
The company is partnered with Biogen Idec on the multiple sclerosis drug Tysabri.
Tysabri is approaching the $1 billion-a-year blockbuster threshold. Worldwide sales of the drug were $218 million in the fourth quarter of 2008, up from $129 million the previous year.
Biogen is a logical acquirer of Elan, Conover says. Buying Elan would give Biogen all of Tysabri.
Elan, in partnership with Wyeth -- soon to be Pfizer -- also has a phase three trial underway for bapineuzumab, a biologic to fight Alzheimer's.
The drug would be approved by regulators even if it gave only a small improvement, Conover says.
That's because the currently available drugs treat only Alzheimer's symptoms -- and not very well.
Biogen is also a potential takeover target, Conover says. It ranks in his report as the second most likely biotech to be acquired
The report puts Rigel Pharmaceuticals (RIGL), NeurogesX (NGSX) and Vertex Pharmaceuticals (VRTX) in third, fourth and fifth places, respectively.
Big biotechs likely to do the acquiring include Gilead, Amgen, Celgene and Cephalon (CEPH).
(Source: iStockAnalyst )
Friday, March 20, 2009 6:13 PM
Mar. 20, 2009 (Investor's Business Daily) -- Much of the drug industry's attention has recently focused on mergers and acquisitions by the biggest of Big Pharma, including much-hyped unions between Pfizer and Wyeth, Merck and Schering-Plough, and Roche and Genentech.
Less attention has been paid to consolidation in the biotech sector, though some experts expect plenty of activity there, too.
In fact, it's already happening.
Roche's (RHHBY) March 12 buy of 100% of Genentech was one example.
Another is last week's announcement by Gilead Sciences (GILD) it will buy fellow biotech CV Therapeutics (CVTX). CV's board unanimously recommended shareholders accept Gilead's $20-a-share cash offer.
The deal is worth $1.4 billion. That's small potatoes compared to Pfizer's $60 billion for Wyeth (WYE) or Merck's (MRK) $4.1 billion, but it's still a harbinger, observers say.
There are plenty of M&A prospects within biotech's own community, says Michael Becker, president and CEO of consulting firm MD Becker Partners.
Biotech has different needs from Big Pharma, says Becker, a former CEO at both Cytogen and VioQuest Pharmaceuticals.
Pharma is cash-rich but pipeline poor. In contrast, biotechs might have promising pipelines, but don't have much cash.
A handful of biotechs are profitable, but they tend to be the industry's biggest names. The list includes Gilead, Amgen (AMGN), Celgene (CELG), Genzyme (GENZ) and Biogen Idec (BIIB).
Becker expects one of two things to happen soon.
"We'll see either a lot of companies disappear after their funds run out, or we'll see a wave of consolidation in biotech," he said.
He reckons 120 biotechs will run out of cash in three months or less.
With only speculative science as collateral, most small biotechs can't borrow in this market. And most can't go public, either, because it's a bad market for IPOs.
In a nutshell, small-cap biotech funding is broken, says Jason Kantor, analyst with RBC Capital Markets. "We're seeing a lot of small-cap companies swallowing the bitter pill, cutting people and programs."
While biotechs have not been afraid of being acquired by rich drugmakers, biotechs being bought by fellow biotechs is more attractive because it allows two entrepreneurial and innovative organizations to grow together, Becker says.
Many of the bigger biotechs might start pouncing as their smaller brethren grow more desperate to cash in.
"If you're Amgen or Biogen Idec, you're probably sitting on the sidelines waiting for companies to start running out of capital," Becker said.
Gilead outbid Japan's Astellas to get CV Therapeutics, which has never turned a profit. Gilead specializes in HIV/AIDS and liver disease treatments. It made the buy to grow its cardiac business.
Mergers within the biotech community are probable, says Kantor.
That's partly because biotechs buying biotechs need not fear a bidding war with Big Pharma. The recent activity showed that big drugmakers have a low appetite for risk, even though they know they need to do something about their pipelines, Kantor says.
Even Roche's buy of the remaining shares of Genentech it didn't previously own was more about saving money than expanding research.
"They're more comfortable with mergers that have cost savings as a major component of growth than they are with the high risk of clinical trials that come with buying more innovative growth companies," Kantor said.
Meanwhile, small cap biotechs, faced with a capital drought, will be more willing sellers. The buyers would be not only large biotechs but even some midcap biotechs that have cash.
Biotech buyers of biotech will be selective. They're more likely to put money into smaller biotechs that have products completing phase three clinical trials, Kantor says. "People don't like to buy early clinical trial risk."
He cites data showing that from 2005 to 2008, 80% of biotechs acquired had products on the market or had completed phase three.
In some cases, science won't be the motivation for an acquisition. Gilead bought CV Therapeutics for its sales force, Kantor says.
If cash-poor biotechs don't merge, they'll at least have to delay product development, says Damien Conover, Morningside biotech analyst and co-author of a report grading 63 biotechs by acquisition probability.
The top target is Ireland's Elan (ELN), developer of autoimmune and neurodegenerative therapies.
The company is partnered with Biogen Idec on the multiple sclerosis drug Tysabri.
Tysabri is approaching the $1 billion-a-year blockbuster threshold. Worldwide sales of the drug were $218 million in the fourth quarter of 2008, up from $129 million the previous year.
Biogen is a logical acquirer of Elan, Conover says. Buying Elan would give Biogen all of Tysabri.
Elan, in partnership with Wyeth -- soon to be Pfizer -- also has a phase three trial underway for bapineuzumab, a biologic to fight Alzheimer's.
The drug would be approved by regulators even if it gave only a small improvement, Conover says.
That's because the currently available drugs treat only Alzheimer's symptoms -- and not very well.
Biogen is also a potential takeover target, Conover says. It ranks in his report as the second most likely biotech to be acquired
The report puts Rigel Pharmaceuticals (RIGL), NeurogesX (NGSX) and Vertex Pharmaceuticals (VRTX) in third, fourth and fifth places, respectively.
Big biotechs likely to do the acquiring include Gilead, Amgen, Celgene and Cephalon (CEPH).
(Source: iStockAnalyst )
PIZZODIGINO
Pacifico
Non leggo e non scrivo ma ci sono sempre e ho ancora tutte le azioni; un saluto a tutti gli amici nicoxiani.
jenJEN
Mai domi!
Saluti a te fratello!
magolibero
..se la sà gira..
magolibero
..se la sà gira..
Doctor.. tu vedi tutto
ma doveva chiudere per forzza a 8.20 ??
avevo visto il book poco prima della chiusura del'asta e se non ricordo male fra quelli al meglio e quelli a 8.41 eran quasi 3.000 pezzi (..sempre appunto se non ho preso un abbaglio..)
ma doveva chiudere per forzza a 8.20 ??
avevo visto il book poco prima della chiusura del'asta e se non ricordo male fra quelli al meglio e quelli a 8.41 eran quasi 3.000 pezzi (..sempre appunto se non ho preso un abbaglio..)
doctor NO
NO nel DNA
- Stato